Study shows effectiveness of artesunate, a common herbal-based anti-malarial drug, in controlling asthma

August 1, 2014
Dr Eugene Ho (left) of the NUS Saw Swee Hock School of Public Health and Associate Professor Fred Wong (right) of the NUS Yong Loo Lin School of Medicine discovered that artesunate can be used as an anti-inflammatory drug to control asthma, with potentially lower side effects than other drugs currently available. Credit: National University of Singapore

Asthmatic patients may soon have a more effective way to control the condition, thanks to a new pharmacological discovery by researchers from the National University of Singapore (NUS).

The team, led by Associate Professor Fred Wong from the Department of Pharmacology at the NUS Yong Loo Lin School of Medicine, together with Dr Eugene Ho Wanxing, a recent PhD graduate from the Saw Swee Hock School of Public Health at NUS, discovered that , a common herbal-based anti-malarial drug, can be used to control asthma, with better treatment outcomes than other drugs currently available.

In their latest work, the team revealed for the first time that artesunate is able to suppress airway inflammation and produce an array of anti-inflammatory effects similar to those by dexamethasone, the most potent steroid currently available, and with less side effects. This breakthrough discovery was first published in the journal Metabolomics on 16 July 2014.

Earlier this year, the NUS team was invited by renowned journal Pharmacology and Therapeutics to pen a comprehensive review of the pharmacological effects of artesunate, and the review article was published in the journal in April 2014.

The quest for better asthma therapeutics

Asthma is an incurable lung disease that inflames and narrows the airways, causing recurring periods of wheezing, chest tightness, coughing and shortness of breath. It is a chronic condition that affects people of all ages, but it most often starts during childhood.

To address the global unmet demand for better therapeutics to control allergic asthma, Dr Ho explored the therapeutic values of artesunate, which is herbal-based, as an alternative drug candidate. This study was part of Dr Ho's final-year project when he was pursuing a Bachelor of Science in Life Sciences at NUS. His initial findings demonstrated that artesunate possessed promising anti-inflammatory potential.

Dr Ho was recognised by the Singapore-MIT Alliance (SMA) in 2010 for his novel discovery, and he was awarded the SMA Graduate Fellowship for his PhD studies at NUS.

For his postgraduate studies, Dr Ho built upon his findings to better understand the therapeutic properties and molecular mechanisms of artesunate under the supervision of Assoc Prof Fred Wong.

The NUS team studied the therapeutic effects of artesunate against oxidative stress and oxidative lung damage which are major inflammatory events that contribute to the severity of asthma attacks. They found that artesunate could better prevent oxidative lung damage, a major molecular inflammatory event in asthmatic lungs, than clinically-used corticosteroid, dexamethasone.

Their collective results revealed that artesunate can be used to better control asthma, with improved outcomes and lesser adverse effects than currently available drugs. As long term usage of steroids may induce many potential in asthmatic patients, the significance of this study suggests that the patients may eventually be able to adopt artesunate as a safer and more effective alternative to control their asthma.

The next step

Moving forward, the team led by Assoc Prof Wong will further explore the therapeutic and pharmacological effects of artesunate for asthma, as well as for other medical conditions. They also intend to work with industry partners to test the effects of artesunate on asthmatic patients.

Dr Ho is also furthering his research as a Research Fellow at the Saw Swee Hock School of Public Health at NUS, where he is investigating the molecular mechanisms of artesunate, and hopes to discover more beneficial effects of artesunate and accelerate the adoption of this drug for clinical tests.

Explore further: Malaria drug association with hemolytic anemia unclear

More information: "Anti-malarial drug artesunate restores metabolic changes in experimental allergic asthma Metabolomics (2014): 1-11 , July 16, 2014

"Artemisinins: Pharmacological actions beyond anti-malarial" Pharmacology & Therapeutics, Volume 142, Issue 1, April 2014, Pages 126–139

Related Stories

Malaria drug association with hemolytic anemia unclear

January 11, 2013
(HealthDay)—Artesunate, a drug used in the treatment of severe malaria, may or may not be associated with hemolytic anemia, so the U.S. Centers for Disease Control and Prevention recommends close monitoring of patients ...

Rectal artesunate beneficial in young children with severe malaria, but may be harmful in older children, adults

May 30, 2014
Researchers from the Cochrane Infectious Diseases Group, hosted at LSTM, conducted an independent review of the effects of pre-referral rectal artesunate for people with severe malaria, published in the Cochrane Library today.

New combination malaria treatment equally effective

April 5, 2012
(HealthDay) -- Fixed-dose, combination pyronaridine-artesunate treatment is as effective as mefloquine plus artesunate in treating malaria infection, according to a study published in the April 5 issue of the New England ...

Cochrane review of dihydroartemisinin-piperaquine for treating uncomplicated malaria

January 21, 2014
'Dihydroartemisinin-piperaquine is more effective than artemether-lumefantrine, and has fewer side effects than artesunate-mefloquine' concludes a systematic review published by the Cochrane Infectious Disease Group, hosted ...

Researchers are now a step closer to finding treatment for dengue fever

July 31, 2014
There have been several news reports that the world's first dengue vaccine will be available next year. However, the latest clinical trials show that the vaccine only provides a protection of around 50 per cent for DENV-2 ...

Recommended for you

New insights into protein's role in inflammatory response

July 28, 2017
A protein called POP2 inhibits a key inflammatory pathway, calming the body's inflammatory response before it can become destructive, Northwestern Medicine scientists have demonstrated in mouse models.

Targeting 'broken' metabolism in immune cells reduces inflammatory disease

July 12, 2017
The team, led by researchers at Imperial College London, Queen Mary University of London and Ergon Pharmaceuticals, believes the approach could offer new hope in the treatment of inflammatory conditions like arthritis, autoimmune ...

A perturbed skin microbiome can be 'contagious' and promote inflammation, study finds

June 29, 2017
Even in healthy individuals, the skin plays host to a menagerie of bacteria, fungi and viruses. Growing scientific evidence suggests that this lively community, collectively known as the skin microbiome, serves an important ...

Inflammatory bowel disease: Scientists zoom in on genetic culprits

June 28, 2017
Scientists have closed in on specific genes responsible for Inflammatory Bowel Disease (IBD) from a list of over 600 genes that were suspects for the disease. The team from the Wellcome Trust Sanger Institute and their collaborators ...

Trials show unique stem cells a potential asthma treatment

June 28, 2017
A study led by scientists at Monash University has shown that a new therapy developed through stem cell technology holds promise as a treatment for chronic asthma.

Researchers find piece in inflammatory disease puzzle

May 23, 2017
Inflammation is the process by which the body responds to injury or infection but when this process becomes out of control it can cause disease. Monash Biomedicine Discovery Institute (BDI) researchers, in collaboration with ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.